Onychomycosis - Drug Pipeline Landscape, 2023

Onychomycosis - Drug Pipeline Landscape, 2023

Onychomycosis is a fungal infection of the nail plate, nail bed, or both. Infection may be distal subungual, with nail thickening and yellowing and accumulation of keratin and debris underneath the nail, proximal subungual or white superficial with spreading of chalky white scale beneath the nail surface.

Onychomycosis is caused by 3 main classes of fungi: dermatophytes, yeasts, and non-dermatophyte molds. Dermatophytes are by far the most common cause of onychomycosis.

Onychomycosis can cause pain, discomfort, and disfigurement. Onychomycosis is highly prevalent, particularly among older men and patients with compromised distal circulation, nail dystrophies, and/or tinea pedis.

Doctors most often diagnose onychomycosis by examining affected nail for hyphae on potassium hydroxide wet mount and cultured. Although more expensive, PCR has become a more common technique to confirm the diagnosis of onychomycosis. Histopathologic examination of PAS-stained nail clippings and subungual debris may also be helpful.

There are several treatment options for onychomycosis. The most common investigative treatments include new delivery systems for terbinafine. Topical antifungal nail lacquer containing efinaconazole, ciclopirox, or amorolfine is occasionally effective as primary treatment and can improve cure rate when used as an adjunct with oral drugs, particularly in resistant infections.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Onychomycosis treatment such as Efinaconazole, MOB015, BB2603 and others. Key players involved in the development of therapies to treat Onychomycosis are Almirall, AmtixBio Co Ltd, Blueberry Therapeutics, Moberg Pharma AB, NovaBiotics and others. Two drugs are under late-stage pre-registration, seven drugs are in Phase II clinical trials and two drugs are in Phase I clinical trials and some other drugs are under preclinical stages of development.

Report Highlights

Global Insight Service's, Onychomycosis - Drug Pipeline Landscape, 2023 report provides an overview of the Onychomycosis pipeline drugs. This report covers detailed insights on Onychomycosis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Onychomycosis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.